Login / Signup

GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Ka Young KimKi Young ShinKeun-A Chang
Published in: Cells (2023)
Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood biomarkers, recent studies have identified other reliable candidates that can serve as measurable indicators of pathological conditions. One such candidate is the glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein that can be detected in blood samples. Increasing evidence suggests that blood GFAP levels can be used to detect early-stage AD. In this systematic review and meta-analysis, we aimed to evaluate GFAP in peripheral blood as a biomarker for AD and provide an overview of the evidence regarding its utility. Our analysis revealed that the GFAP level in the blood was higher in the Aβ-positive group than in the negative groups, and in individuals with AD or mild cognitive impairment (MCI) compared to the healthy controls. Therefore, we believe that the clinical use of blood GFAP measurements has the potential to accelerate the diagnosis and improve the prognosis of AD.
Keyphrases
  • mild cognitive impairment
  • cognitive decline
  • early stage
  • peripheral blood
  • squamous cell carcinoma
  • neuropathic pain
  • amino acid
  • single cell
  • spinal cord
  • binding protein
  • locally advanced